JPRN-UMIN000018754
Completed
未知
Dapagliflozin effectiveness on the vascular endothelial function and glycemic control in T2D with moderately inadequate glycemic control - Dapagliflozin effectiveness on the vascular endothelial function and glycemic control (DEFENCE study)
Japan Society for Patient Report Outcome0 sites80 target enrollmentAugust 21, 2015
ConditionsType 2 diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Japan Society for Patient Report Outcome
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who fall into any of the following criteria are excluded from participating in the study. 1\. Type 1 diabetes or secondary diabetes 2\. Had used SGLT2 inhibitors, GLP\-1 agonists, or insulin 12 weeks before providing their consent 3\. Had used a dose of metformin exceeding 750mg per day 12 weeks before providing their consent 4\. Had started taking angiotensin\-converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor antagonist (ARB), HMG\-CoA reductase inhibitor (statin), or antiplatelet drugs, or had their medication dose changed (including reducing the dose) 12 weeks before providing their consent 5\. Patients who have a severe infection, have had or are about to have surgery, or are suffering from a serious trauma 6\. With a medical history of myocardial infarction, angina, stroke or cerebral infarction 7\. With atrial (chronic) fibrillation, frequent supraventricular or ventricular ectopy 8\. With a moderate or severe level of cardiac insufficiency (patients with class III or more as classified by the NYHA/New York Heart Association) 9\. Ankle Brachial Pressure Index (ABI)\< 0\.9 10\. Serious liver or renal functional failure (serum creatinine 1\.3mg/dL or greater, or eGFR\< 45mL/min/1\.73 square meters) 11\. Unstable blood pressure or lipid abnormalities within 12 weeks before providing their consent 12\. Addicted to alcohol or drugs 13\. Patients who are pregnant or breastfeeding, or who may be, or plan to be, pregnant 14\. Dehydrated (abnormal test results of hematocrit and BUN values, and complaint of symptoms of dehydration) 15\. Using diuretics 16\. Urinary tract or genital infections within 12 weeks before providing their consent 17\. With a past history of hypersensitivity to the study drug 18\. At risks of ketoacidosis, diabetic coma or precoma 19\. Other conditions considered to be unsuitable by the attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Dapagliflozin in Pulmonary Arterial HypertensioPulmonary arterial hypertension.Primary pulmonary hypertensionI27. 0IRCT20200209046427N2Shahid Beheshti University of Medical Sciences100
Completed
Phase 2
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)Renal Insufficiency, ChronicNCT04930549University Hospital, Rouen32
Active, not recruiting
Phase 1
Effect of Empagliflozin on Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 DiabetesPatients with Type 2 diabetes mellitusTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-000172-19-DERWTH Aachen University for the Medical Faculty, represented by Center for Transitional & Clinical Research Aachen (CTC-A44
Completed
Phase 3
Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium ContentDiabetes Mellitus Type 2NCT02383238University of Erlangen-Nürnberg Medical School59
Active, not recruiting
Phase 1
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for type 2 diabetes on cardiovascular events.EUCTR2013-000239-28-NLAstraZeneca AB17,150